Ifrah Financial Services Inc. Acquires New Shares in Halozyme Therapeutics, Inc. $HALO

Ifrah Financial Services Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,029 shares of the biopharmaceutical company’s stock, valued at approximately $454,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC raised its position in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the period. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the period. Clearstead Advisors LLC grew its holdings in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 265 shares during the period. Harbour Investments Inc. increased its stake in Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Wexford Capital LP bought a new stake in Halozyme Therapeutics in the third quarter valued at approximately $70,000. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. UBS Group reiterated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Up 0.0%

Halozyme Therapeutics stock opened at $74.96 on Monday. The stock has a market capitalization of $8.89 billion, a PE ratio of 26.96, a price-to-earnings-growth ratio of 0.31 and a beta of 0.88. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a 50 day moving average of $68.42 and a 200-day moving average of $68.90.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the prior year, the firm earned $1.11 earnings per share. The firm’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 93,250 shares of company stock valued at $6,299,746. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.